| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Models, Genetic | 9 | 2011 | 3493 | 1.170 |
Why?
|
| Models, Statistical | 11 | 2019 | 5100 | 1.110 |
Why?
|
| Likelihood Functions | 4 | 2018 | 1003 | 0.820 |
Why?
|
| Metabolic Diseases | 2 | 2020 | 657 | 0.810 |
Why?
|
| Multifactorial Inheritance | 4 | 2022 | 1190 | 0.810 |
Why?
|
| Genome-Wide Association Study | 12 | 2022 | 12220 | 0.780 |
Why?
|
| Software Validation | 1 | 2021 | 59 | 0.780 |
Why?
|
| Synteny | 1 | 2020 | 79 | 0.770 |
Why?
|
| Systemic Inflammatory Response Syndrome | 2 | 2022 | 609 | 0.720 |
Why?
|
| Polymorphism, Single Nucleotide | 17 | 2020 | 15494 | 0.700 |
Why?
|
| HIV-1 | 22 | 2015 | 6934 | 0.600 |
Why?
|
| Genetic Loci | 3 | 2016 | 2572 | 0.580 |
Why?
|
| Gene Expression Profiling | 5 | 2020 | 9410 | 0.570 |
Why?
|
| Atrial Fibrillation | 3 | 2022 | 5019 | 0.500 |
Why?
|
| Haplotypes | 5 | 2008 | 2781 | 0.460 |
Why?
|
| HIV Infections | 30 | 2019 | 16678 | 0.460 |
Why?
|
| Anti-HIV Agents | 15 | 2015 | 4250 | 0.440 |
Why?
|
| Genotype | 14 | 2011 | 12946 | 0.440 |
Why?
|
| Antiretroviral Therapy, Highly Active | 8 | 2012 | 1872 | 0.420 |
Why?
|
| Bayes Theorem | 4 | 2020 | 2303 | 0.420 |
Why?
|
| Algorithms | 7 | 2021 | 13853 | 0.410 |
Why?
|
| Photoplethysmography | 2 | 2022 | 56 | 0.400 |
Why?
|
| Blood Sedimentation | 2 | 2022 | 231 | 0.380 |
Why?
|
| Cardiovascular Diseases | 8 | 2022 | 15108 | 0.380 |
Why?
|
| Dyslipidemias | 6 | 2022 | 848 | 0.360 |
Why?
|
| Brain Injuries | 4 | 2022 | 2024 | 0.360 |
Why?
|
| Obesity | 6 | 2022 | 12705 | 0.350 |
Why?
|
| Biostatistics | 1 | 2011 | 160 | 0.340 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 2 | 2022 | 425 | 0.340 |
Why?
|
| Electrocardiography, Ambulatory | 2 | 2022 | 585 | 0.330 |
Why?
|
| Research Design | 2 | 2021 | 5979 | 0.320 |
Why?
|
| Indinavir | 3 | 2003 | 74 | 0.310 |
Why?
|
| Lipase | 5 | 2008 | 315 | 0.310 |
Why?
|
| Genomics | 3 | 2020 | 5692 | 0.280 |
Why?
|
| Humans | 87 | 2024 | 742088 | 0.280 |
Why?
|
| Observation | 1 | 2008 | 312 | 0.280 |
Why?
|
| Genetic Association Studies | 2 | 2018 | 2699 | 0.280 |
Why?
|
| CD4-Positive T-Lymphocytes | 11 | 2019 | 4379 | 0.280 |
Why?
|
| Longitudinal Studies | 5 | 2022 | 13921 | 0.270 |
Why?
|
| Disease | 1 | 2011 | 681 | 0.270 |
Why?
|
| Data Interpretation, Statistical | 3 | 2007 | 2714 | 0.260 |
Why?
|
| Computational Biology | 2 | 2015 | 3518 | 0.260 |
Why?
|
| Apolipoprotein C-III | 1 | 2006 | 202 | 0.250 |
Why?
|
| Cervix Uteri | 3 | 2019 | 591 | 0.250 |
Why?
|
| Virus Integration | 4 | 2015 | 297 | 0.240 |
Why?
|
| Interferon-alpha | 3 | 2013 | 895 | 0.240 |
Why?
|
| Regression Analysis | 2 | 2011 | 6452 | 0.240 |
Why?
|
| HIV Protease Inhibitors | 3 | 2006 | 430 | 0.240 |
Why?
|
| Mucous Membrane | 2 | 2019 | 670 | 0.240 |
Why?
|
| Macrophage Activation | 2 | 2017 | 558 | 0.230 |
Why?
|
| Cholesterol, LDL | 1 | 2013 | 2354 | 0.230 |
Why?
|
| Endotoxemia | 2 | 2017 | 206 | 0.220 |
Why?
|
| Myocardium | 1 | 2016 | 4775 | 0.220 |
Why?
|
| Computer Simulation | 6 | 2017 | 6191 | 0.210 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 2 | 2019 | 570 | 0.210 |
Why?
|
| CD4 Lymphocyte Count | 8 | 2014 | 2557 | 0.210 |
Why?
|
| Gene Dosage | 1 | 2007 | 1251 | 0.210 |
Why?
|
| Lipids | 2 | 2013 | 3302 | 0.210 |
Why?
|
| Vagina | 2 | 2019 | 825 | 0.200 |
Why?
|
| Simian immunodeficiency virus | 2 | 2019 | 846 | 0.200 |
Why?
|
| Virus Replication | 5 | 2015 | 2531 | 0.200 |
Why?
|
| Renal Insufficiency, Chronic | 4 | 2019 | 2195 | 0.200 |
Why?
|
| Databases, Genetic | 2 | 2020 | 1780 | 0.190 |
Why?
|
| Triglycerides | 2 | 2006 | 2450 | 0.190 |
Why?
|
| Coma, Post-Head Injury | 1 | 2020 | 21 | 0.190 |
Why?
|
| Prospective Studies | 13 | 2023 | 53187 | 0.190 |
Why?
|
| Principal Component Analysis | 1 | 2023 | 939 | 0.180 |
Why?
|
| Viral Load | 8 | 2015 | 3292 | 0.180 |
Why?
|
| Consciousness Disorders | 2 | 2021 | 418 | 0.180 |
Why?
|
| Heredity | 1 | 2020 | 154 | 0.180 |
Why?
|
| Adult | 36 | 2024 | 213712 | 0.180 |
Why?
|
| Phenotype | 8 | 2019 | 16331 | 0.180 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2020 | 17400 | 0.180 |
Why?
|
| Leukocyte Count | 2 | 2022 | 1583 | 0.170 |
Why?
|
| Semen | 2 | 2019 | 316 | 0.170 |
Why?
|
| Inflammation | 4 | 2021 | 10578 | 0.170 |
Why?
|
| C-Reactive Protein | 2 | 2022 | 3766 | 0.170 |
Why?
|
| Female | 45 | 2023 | 379592 | 0.170 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2020 | 221 | 0.170 |
Why?
|
| Ferritins | 1 | 2022 | 590 | 0.170 |
Why?
|
| Hospital Mortality | 3 | 2022 | 5310 | 0.170 |
Why?
|
| Male | 37 | 2023 | 349538 | 0.160 |
Why?
|
| Blast Injuries | 1 | 2022 | 302 | 0.160 |
Why?
|
| Sampling Studies | 1 | 2020 | 623 | 0.160 |
Why?
|
| Electrocardiography | 2 | 2022 | 6440 | 0.160 |
Why?
|
| Middle Aged | 30 | 2023 | 213127 | 0.160 |
Why?
|
| Multicenter Studies as Topic | 1 | 2023 | 1661 | 0.160 |
Why?
|
| Selection Bias | 1 | 2020 | 369 | 0.160 |
Why?
|
| Disease Progression | 5 | 2024 | 13256 | 0.150 |
Why?
|
| Polyethylene Glycols | 2 | 2013 | 1181 | 0.150 |
Why?
|
| Confidentiality | 1 | 2021 | 609 | 0.140 |
Why?
|
| Hospitals, General | 1 | 2020 | 749 | 0.140 |
Why?
|
| Niacin | 1 | 2017 | 116 | 0.140 |
Why?
|
| Causality | 1 | 2022 | 1265 | 0.140 |
Why?
|
| Aged | 20 | 2022 | 162944 | 0.130 |
Why?
|
| Dendritic Cells | 4 | 2015 | 2723 | 0.130 |
Why?
|
| Artificial Intelligence | 1 | 2008 | 2187 | 0.130 |
Why?
|
| Linkage Disequilibrium | 2 | 2017 | 1995 | 0.130 |
Why?
|
| Chemokine CX3CL1 | 1 | 2015 | 58 | 0.130 |
Why?
|
| Macrophages | 3 | 2022 | 5655 | 0.120 |
Why?
|
| Glutathione Transferase | 2 | 2007 | 595 | 0.120 |
Why?
|
| Probability | 1 | 2020 | 2502 | 0.120 |
Why?
|
| Cytochrome P-450 Enzyme System | 2 | 2007 | 419 | 0.120 |
Why?
|
| Disease Susceptibility | 3 | 2016 | 1780 | 0.120 |
Why?
|
| Biometry | 1 | 2017 | 558 | 0.120 |
Why?
|
| Linear Models | 3 | 2017 | 5948 | 0.120 |
Why?
|
| Open Reading Frames | 1 | 2017 | 810 | 0.120 |
Why?
|
| Military Personnel | 1 | 2022 | 1132 | 0.110 |
Why?
|
| Myocardial Infarction | 4 | 2016 | 11690 | 0.110 |
Why?
|
| Hypothermia, Induced | 1 | 2018 | 747 | 0.110 |
Why?
|
| Intensive Care Units | 3 | 2022 | 3679 | 0.110 |
Why?
|
| Lipopolysaccharides | 3 | 2022 | 2211 | 0.110 |
Why?
|
| DNA, Viral | 2 | 2012 | 2224 | 0.110 |
Why?
|
| Cross-Sectional Studies | 9 | 2024 | 24913 | 0.110 |
Why?
|
| Pedigree | 1 | 2020 | 4646 | 0.110 |
Why?
|
| Hospitalization | 5 | 2023 | 10232 | 0.110 |
Why?
|
| Viremia | 5 | 2012 | 735 | 0.110 |
Why?
|
| Language | 1 | 2021 | 1458 | 0.100 |
Why?
|
| Interferons | 1 | 2015 | 704 | 0.100 |
Why?
|
| Interleukin-6 | 1 | 2022 | 3199 | 0.100 |
Why?
|
| Body Composition | 1 | 2021 | 2400 | 0.100 |
Why?
|
| Bacterial Translocation | 1 | 2011 | 73 | 0.100 |
Why?
|
| Chemokine CXCL12 | 1 | 2013 | 462 | 0.100 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2011 | 66 | 0.100 |
Why?
|
| Endometrium | 1 | 2014 | 424 | 0.100 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2022 | 1499 | 0.100 |
Why?
|
| Brain Concussion | 1 | 2022 | 1318 | 0.100 |
Why?
|
| Cholesterol, HDL | 2 | 2008 | 1813 | 0.100 |
Why?
|
| Meta-Analysis as Topic | 1 | 2016 | 1342 | 0.100 |
Why?
|
| Protein Precursors | 1 | 2015 | 1154 | 0.100 |
Why?
|
| Alternative Splicing | 1 | 2016 | 1118 | 0.090 |
Why?
|
| Gene Frequency | 2 | 2008 | 3587 | 0.090 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2018 | 1016 | 0.090 |
Why?
|
| Antiviral Agents | 2 | 2013 | 2978 | 0.090 |
Why?
|
| Retrospective Studies | 7 | 2023 | 77098 | 0.090 |
Why?
|
| Resource Allocation | 1 | 2012 | 341 | 0.090 |
Why?
|
| Cohort Studies | 11 | 2023 | 40450 | 0.090 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2013 | 604 | 0.090 |
Why?
|
| Cluster Analysis | 4 | 2009 | 2713 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2017 | 4751 | 0.080 |
Why?
|
| Inpatients | 1 | 2020 | 2495 | 0.080 |
Why?
|
| Anti-Retroviral Agents | 3 | 2009 | 1712 | 0.080 |
Why?
|
| Severity of Illness Index | 3 | 2021 | 15530 | 0.080 |
Why?
|
| Risk Factors | 9 | 2024 | 72145 | 0.080 |
Why?
|
| Statistical Distributions | 1 | 2008 | 64 | 0.080 |
Why?
|
| Oxidoreductases, N-Demethylating | 1 | 2008 | 115 | 0.080 |
Why?
|
| AIDS Serodiagnosis | 1 | 2009 | 184 | 0.080 |
Why?
|
| Antigens, Viral | 1 | 2012 | 1034 | 0.080 |
Why?
|
| Autoantigens | 1 | 2012 | 891 | 0.080 |
Why?
|
| Immunity, Humoral | 1 | 2012 | 596 | 0.080 |
Why?
|
| Electronic Health Records | 2 | 2023 | 4440 | 0.080 |
Why?
|
| Ketamine | 1 | 2013 | 499 | 0.080 |
Why?
|
| RNA | 1 | 2017 | 2747 | 0.080 |
Why?
|
| Brucella abortus | 1 | 2006 | 12 | 0.070 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2008 | 257 | 0.070 |
Why?
|
| Protease Inhibitors | 1 | 2011 | 790 | 0.070 |
Why?
|
| Aged, 80 and over | 6 | 2022 | 57683 | 0.070 |
Why?
|
| Brucellosis | 1 | 2006 | 20 | 0.070 |
Why?
|
| Sex Factors | 1 | 2021 | 10392 | 0.070 |
Why?
|
| Killer Cells, Natural | 3 | 2011 | 2133 | 0.070 |
Why?
|
| Benzoxazines | 1 | 2008 | 301 | 0.070 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2021 | 3038 | 0.070 |
Why?
|
| Thyrotoxicosis | 1 | 2007 | 82 | 0.070 |
Why?
|
| Cerebral Hemorrhage | 1 | 2018 | 2643 | 0.070 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2022 | 3239 | 0.070 |
Why?
|
| Immunity, Innate | 3 | 2007 | 2956 | 0.070 |
Why?
|
| Atherosclerosis | 1 | 2022 | 3428 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2020 | 11695 | 0.070 |
Why?
|
| South Africa | 4 | 2011 | 1728 | 0.070 |
Why?
|
| Treatment Outcome | 8 | 2022 | 62966 | 0.070 |
Why?
|
| Lipid Metabolism | 2 | 2011 | 1887 | 0.070 |
Why?
|
| Health Resources | 1 | 2012 | 911 | 0.070 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2015 | 4438 | 0.060 |
Why?
|
| Consciousness | 2 | 2020 | 571 | 0.060 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2016 | 1728 | 0.060 |
Why?
|
| Apolipoprotein A-I | 1 | 2006 | 280 | 0.060 |
Why?
|
| Plasmodium | 1 | 2007 | 248 | 0.060 |
Why?
|
| Bacteremia | 1 | 2011 | 962 | 0.060 |
Why?
|
| Apolipoproteins | 1 | 2007 | 315 | 0.060 |
Why?
|
| Recovery of Function | 2 | 2021 | 2924 | 0.060 |
Why?
|
| Interleukin-12 | 1 | 2006 | 579 | 0.060 |
Why?
|
| Brain Ischemia | 1 | 2018 | 3258 | 0.060 |
Why?
|
| Telemedicine | 1 | 2021 | 2853 | 0.060 |
Why?
|
| Nelfinavir | 1 | 2003 | 68 | 0.060 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2012 | 2231 | 0.060 |
Why?
|
| Genome, Human | 1 | 2016 | 4420 | 0.050 |
Why?
|
| Receptors, CCR5 | 2 | 2019 | 497 | 0.050 |
Why?
|
| Aging | 1 | 2022 | 8626 | 0.050 |
Why?
|
| Antibodies, Neutralizing | 1 | 2012 | 1970 | 0.050 |
Why?
|
| HIV | 2 | 2011 | 1600 | 0.050 |
Why?
|
| Leptin | 1 | 2010 | 1593 | 0.050 |
Why?
|
| Lymphocyte Activation | 5 | 2015 | 5519 | 0.050 |
Why?
|
| Stavudine | 2 | 2012 | 85 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2020 | 23320 | 0.050 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2022 | 198 | 0.050 |
Why?
|
| Asthma | 1 | 2020 | 5955 | 0.050 |
Why?
|
| Pharmacogenetics | 1 | 2006 | 676 | 0.050 |
Why?
|
| Coronary Vessels | 1 | 2013 | 3099 | 0.050 |
Why?
|
| Molecular Sequence Data | 3 | 2006 | 18112 | 0.050 |
Why?
|
| Adiposity | 1 | 2011 | 1806 | 0.050 |
Why?
|
| Software | 1 | 2015 | 4434 | 0.050 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2002 | 459 | 0.050 |
Why?
|
| Saquinavir | 1 | 2000 | 28 | 0.050 |
Why?
|
| Young Adult | 4 | 2021 | 56350 | 0.050 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2011 | 1825 | 0.050 |
Why?
|
| Amino Acid Sequence | 2 | 2003 | 13814 | 0.050 |
Why?
|
| Spleen | 1 | 2006 | 2359 | 0.050 |
Why?
|
| Macaca mulatta | 2 | 2019 | 2378 | 0.050 |
Why?
|
| Intubation | 1 | 2020 | 141 | 0.050 |
Why?
|
| Ritonavir | 2 | 2012 | 322 | 0.040 |
Why?
|
| Respiratory Therapy | 1 | 2020 | 132 | 0.040 |
Why?
|
| Monocytes | 1 | 2009 | 2593 | 0.040 |
Why?
|
| Headache | 1 | 2007 | 1219 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2017 | 12071 | 0.040 |
Why?
|
| T-Lymphocytes | 2 | 2015 | 10163 | 0.040 |
Why?
|
| Tuberculosis | 1 | 2011 | 1904 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2016 | 11470 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2022 | 8297 | 0.040 |
Why?
|
| Attitude | 1 | 2023 | 772 | 0.040 |
Why?
|
| Antipyretics | 1 | 2018 | 23 | 0.040 |
Why?
|
| Multigene Family | 1 | 2002 | 1102 | 0.040 |
Why?
|
| Coma | 1 | 2022 | 475 | 0.040 |
Why?
|
| Massachusetts | 2 | 2021 | 8662 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2020 | 9846 | 0.040 |
Why?
|
| Malaria | 1 | 2007 | 1232 | 0.040 |
Why?
|
| Boston | 2 | 2020 | 9305 | 0.040 |
Why?
|
| United States | 2 | 2022 | 69693 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2006 | 2899 | 0.040 |
Why?
|
| Drug Resistance, Viral | 1 | 2002 | 820 | 0.040 |
Why?
|
| Drug Administration Schedule | 3 | 2012 | 4929 | 0.040 |
Why?
|
| Diabetes Mellitus | 1 | 2015 | 5724 | 0.030 |
Why?
|
| Adolescent | 2 | 2023 | 85649 | 0.030 |
Why?
|
| Cells, Cultured | 3 | 2017 | 19223 | 0.030 |
Why?
|
| Fatigue | 1 | 2023 | 1526 | 0.030 |
Why?
|
| Lysosomal-Associated Membrane Protein 1 | 1 | 2015 | 26 | 0.030 |
Why?
|
| Stroke | 1 | 2018 | 9963 | 0.030 |
Why?
|
| Pakistan | 1 | 2016 | 296 | 0.030 |
Why?
|
| Delphi Technique | 1 | 2018 | 778 | 0.030 |
Why?
|
| Waist-Hip Ratio | 1 | 2016 | 517 | 0.030 |
Why?
|
| Perforin | 1 | 2015 | 168 | 0.030 |
Why?
|
| Arousal | 1 | 2020 | 1165 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2005 | 4328 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2020 | 2615 | 0.030 |
Why?
|
| Axons | 1 | 2022 | 1681 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2016 | 3920 | 0.030 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2015 | 442 | 0.030 |
Why?
|
| Double-Blind Method | 2 | 2020 | 12017 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2022 | 4200 | 0.030 |
Why?
|
| Prognosis | 4 | 2019 | 29010 | 0.030 |
Why?
|
| HIV Protease | 2 | 2005 | 96 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 2 | 2019 | 5385 | 0.030 |
Why?
|
| Interferon-gamma | 2 | 2015 | 3199 | 0.030 |
Why?
|
| Logistic Models | 2 | 2020 | 13403 | 0.030 |
Why?
|
| Pandemics | 2 | 2023 | 8328 | 0.030 |
Why?
|
| Disease Reservoirs | 1 | 2012 | 131 | 0.030 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2022 | 2304 | 0.030 |
Why?
|
| Protein Interaction Mapping | 1 | 2016 | 627 | 0.030 |
Why?
|
| Respiratory Insufficiency | 1 | 2020 | 1199 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2019 | 1613 | 0.030 |
Why?
|
| Midazolam | 1 | 2013 | 270 | 0.030 |
Why?
|
| Interferon Type I | 1 | 2015 | 542 | 0.030 |
Why?
|
| Time Factors | 5 | 2015 | 40054 | 0.020 |
Why?
|
| Apoptosis | 2 | 2022 | 9715 | 0.020 |
Why?
|
| Cytokines | 2 | 2019 | 7317 | 0.020 |
Why?
|
| Flow Cytometry | 2 | 2011 | 5975 | 0.020 |
Why?
|
| Fever | 1 | 2018 | 1612 | 0.020 |
Why?
|
| Plasma | 1 | 2014 | 575 | 0.020 |
Why?
|
| Serum | 1 | 2011 | 212 | 0.020 |
Why?
|
| Lamivudine | 1 | 2011 | 342 | 0.020 |
Why?
|
| Predictive Value of Tests | 2 | 2005 | 15056 | 0.020 |
Why?
|
| Africa South of the Sahara | 1 | 2012 | 724 | 0.020 |
Why?
|
| Self Report | 1 | 2020 | 3548 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2020 | 2566 | 0.020 |
Why?
|
| Zidovudine | 1 | 2011 | 620 | 0.020 |
Why?
|
| Adipocytes | 1 | 2016 | 1182 | 0.020 |
Why?
|
| Adipose Tissue | 1 | 2021 | 3278 | 0.020 |
Why?
|
| Consensus | 1 | 2018 | 2935 | 0.020 |
Why?
|
| Breast Neoplasms | 2 | 2007 | 20774 | 0.020 |
Why?
|
| Body Fat Distribution | 1 | 2010 | 244 | 0.020 |
Why?
|
| Lymphatic Metastasis | 2 | 2007 | 2906 | 0.020 |
Why?
|
| Incidental Findings | 1 | 2013 | 688 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2002 | 12242 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2016 | 2011 | 0.020 |
Why?
|
| Transfection | 1 | 2016 | 5892 | 0.020 |
Why?
|
| Carbimazole | 1 | 2007 | 4 | 0.020 |
Why?
|
| Alkynes | 1 | 2008 | 306 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2021 | 35342 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2016 | 1707 | 0.020 |
Why?
|
| Mutation | 4 | 2007 | 29717 | 0.020 |
Why?
|
| Receptors, Interleukin-12 | 1 | 2006 | 26 | 0.020 |
Why?
|
| Antithyroid Agents | 1 | 2007 | 68 | 0.020 |
Why?
|
| CD40 Ligand | 1 | 2009 | 526 | 0.020 |
Why?
|
| RNA Interference | 1 | 2016 | 2890 | 0.020 |
Why?
|
| Cyclopropanes | 1 | 2008 | 416 | 0.020 |
Why?
|
| Electroencephalography | 1 | 2022 | 6142 | 0.020 |
Why?
|
| Immune Tolerance | 1 | 2015 | 2257 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2009 | 759 | 0.020 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 2007 | 517 | 0.020 |
Why?
|
| Malaria Vaccines | 1 | 2007 | 158 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2009 | 625 | 0.020 |
Why?
|
| Host-Pathogen Interactions | 1 | 2015 | 1477 | 0.020 |
Why?
|
| Disease-Free Survival | 2 | 2007 | 6891 | 0.020 |
Why?
|
| Comorbidity | 1 | 2020 | 10372 | 0.020 |
Why?
|
| Brain Mapping | 1 | 2021 | 6669 | 0.020 |
Why?
|
| Sexual Behavior | 1 | 2015 | 2050 | 0.020 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 5304 | 0.020 |
Why?
|
| Graves Disease | 1 | 2007 | 241 | 0.020 |
Why?
|
| Registries | 1 | 2021 | 8077 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2011 | 1726 | 0.020 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2005 | 115 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 3585 | 0.020 |
Why?
|
| Triage | 1 | 2012 | 977 | 0.020 |
Why?
|
| Coronary Artery Disease | 1 | 2005 | 6454 | 0.020 |
Why?
|
| Alleles | 1 | 2016 | 6931 | 0.020 |
Why?
|
| Brain | 2 | 2021 | 26343 | 0.020 |
Why?
|
| Smoking | 1 | 2021 | 8969 | 0.020 |
Why?
|
| Plasma Cells | 1 | 2007 | 592 | 0.010 |
Why?
|
| Health Services Needs and Demand | 1 | 2012 | 1411 | 0.010 |
Why?
|
| Mortality | 1 | 2015 | 2857 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2012 | 6171 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2020 | 12695 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 6534 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2012 | 6608 | 0.010 |
Why?
|
| Reproducibility of Results | 2 | 2012 | 19862 | 0.010 |
Why?
|
| Pregnancy | 1 | 2023 | 29087 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2007 | 2236 | 0.010 |
Why?
|
| Markov Chains | 1 | 2005 | 969 | 0.010 |
Why?
|
| Quality of Life | 1 | 2022 | 12730 | 0.010 |
Why?
|
| Animals | 4 | 2019 | 168561 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 2007 | 1606 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 18006 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 12344 | 0.010 |
Why?
|
| Selection, Genetic | 1 | 2005 | 914 | 0.010 |
Why?
|
| Lipoproteins | 1 | 2005 | 876 | 0.010 |
Why?
|
| Monte Carlo Method | 1 | 2005 | 1254 | 0.010 |
Why?
|
| Signal Transduction | 2 | 2016 | 23387 | 0.010 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2007 | 1837 | 0.010 |
Why?
|
| Heterozygote | 1 | 2005 | 2790 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2009 | 2948 | 0.010 |
Why?
|
| Mothers | 1 | 2009 | 2163 | 0.010 |
Why?
|
| Glucose | 1 | 2010 | 4391 | 0.010 |
Why?
|
| Follow-Up Studies | 2 | 2012 | 39004 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 20086 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2006 | 6382 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2009 | 4414 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 2000 | 860 | 0.010 |
Why?
|
| Immunotherapy | 1 | 2012 | 4414 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 7901 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2005 | 4187 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2005 | 6365 | 0.010 |
Why?
|
| Models, Biological | 1 | 2012 | 9581 | 0.010 |
Why?
|
| Base Sequence | 1 | 2006 | 12797 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2005 | 10248 | 0.010 |
Why?
|
| Child | 2 | 2009 | 77478 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2004 | 9144 | 0.010 |
Why?
|
| Infant | 1 | 2011 | 35070 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2007 | 9185 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2006 | 21821 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2007 | 11472 | 0.000 |
Why?
|
| Mice | 1 | 2006 | 81045 | 0.000 |
Why?
|